Chimeric antigen receptor T-cell (CAR-T) therapy is an immunotherapy specifically developed for each individual cancer patient. It involves reprogramming the patient’s own immune cells to target their cancer. It is a highly complex and potentially risky individualised treatment, and is so far only available for people with blood cancers, such as lymphoma and leukaemia.
Researchers from Exuma Biotechnology have developed two CAR-T therapies for kidney cancer patients, and have presented early first-in-human clinical data in 7 Chinese patients with stage 4 renal cell carcinoma (RCC). Six of the 7 patients had stable disease after a median follow-up period of 140 days. The company plan to expand its development programme in China this summer, and will decide whether to expand the programme to the US and Europe by the end of the year.